Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies

Zhiqin Wang; Bowen Wu; Guangjun Nie; Jingyan Wei; Yiye Li

doi:10.1016/j.canlet.2023.216138

Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies

Cancer Lett. 2023 Apr 28:560:216138. doi: 10.1016/j.canlet.2023.216138. Epub 2023 Mar 18.

Authors

Zhiqin Wang¹, Bowen Wu², Guangjun Nie³, Jingyan Wei⁴, Yiye Li⁵

Affiliations

¹ College of Pharmaceutical Science, Jilin University, Changchun, 130021, PR China; Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing, 100049, PR China; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, 100190, PR China.
² Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing, 100049, PR China; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, 100190, PR China; School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, PR China.
³ Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing, 100049, PR China; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, 100190, PR China; GBA National Institute for Nanotechnology Innovation, Guangzhou, 510530, PR China.
⁴ College of Pharmaceutical Science, Jilin University, Changchun, 130021, PR China. Electronic address: jingyanweijluedu@163.com.
⁵ Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing, 100049, PR China; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, 100190, PR China. Electronic address: liyy@nanoctr.cn.

PMID: 36934836
DOI: 10.1016/j.canlet.2023.216138

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal malignancy with insidious onset and early distal metastasis. Metabolic reprogramming, the autonomous changes in cellular bioenergetics driven by aberrant genetic events and crosstalk between cancer and non-cancer cells in the desmoplastic microenvironment, is pivotal for the rapid progression of PDAC. As an attractive therapeutic target, nucleoside metabolism is regulated by various anti-metabolic drugs for the clinical treatment of PDAC. Despite various challenges, such as poor drug delivery efficiency and off-target side effects, metabolic modification and intervention are emerging as promising strategies for PDAC therapy, enabled by the rapid development of nanotechnology-based drug delivery strategies. In this review, we discuss the metabolic characteristics of PDAC and highlight how the development of nanomedicine has boosted the development of new therapeutics for PDAC by modulating critical targets in metabolic reprogramming.

Keywords: Drug delivery; Nanomedicine; Pancreatic ductal adenocarcinoma; Tumor metabolism.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Carcinoma, Pancreatic Ductal* / pathology
Energy Metabolism
Humans
Nanomedicine
Pancreatic Neoplasms* / pathology
Tumor Microenvironment